KR910015309A - 종양괴사인자(tnf) 억제제 및 그 제조방법 - Google Patents

종양괴사인자(tnf) 억제제 및 그 제조방법 Download PDF

Info

Publication number
KR910015309A
KR910015309A KR1019900010841A KR900010841A KR910015309A KR 910015309 A KR910015309 A KR 910015309A KR 1019900010841 A KR1019900010841 A KR 1019900010841A KR 900010841 A KR900010841 A KR 900010841A KR 910015309 A KR910015309 A KR 910015309A
Authority
KR
South Korea
Prior art keywords
tnf inhibitor
tnf
inhibitor
kda
gene
Prior art date
Application number
KR1019900010841A
Other languages
English (en)
Other versions
KR100230156B1 (ko
Inventor
티. 부루어 마이클
케이. 홀 카린
더블유. 킹 마이클
콘호 타다히코
스콰이어스 찰스
씨. 톰슨 로버트
반더슬리스 레베카 더블유
반니스 제임스
Original Assignee
원본미기재
시너겐, 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27409520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR910015309(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 원본미기재, 시너겐, 인크 filed Critical 원본미기재
Publication of KR910015309A publication Critical patent/KR910015309A/ko
Application granted granted Critical
Publication of KR100230156B1 publication Critical patent/KR100230156B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

종양괴사인자(TNF) 억제제 및 그 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 TNF 억제제(30kDa)의 불존재(-.-)및 존재(-x-x)하의 세포독성작용의 검정을 나타낸다. 다양한 농도의 TNF가 TNF 억제제(30kDa)와 함께, 및 TNF 억제제(30kDa)없이 배양되었고, 세포독성작용의 검정은 실시예 1에서와 같이 수행되었다.

Claims (21)

  1. TNF에 대하여 활성인, 본질적으로 정제된 종양괴사인자(TNT) 억제제.
  2. 제1항에 있어서, TNF 억제제가 분량 약 30kDa/당 단백질인 TNF 억제제.
  3. 제2항에 있어서, TNF 억제제가 탈당부가되고 분자량이 약 18kDa인 TNF 억제제.
  4. 제3항에 있어서, TNF 억제제가 재조함 DNA 방법에 의하여 생성되는 TNF 억제제.
  5. 제1항에 있어서, TNF 억제제가 분자량/약 40 kDa의 당 단백질인 TNF 억제제.
  6. 제5항에 있어서, TNF 억제제가 TNF 알파 TNF 베타에 대하여 모두 활성인 TNF 억제제.
  7. 제6항에 있어서, TNF 억제제가 탈당부가된 TNF 억제제.
  8. 제2항에 있어서, TNF 억제제가 제19도에 도시된 아미노산 배열을 갖는 TNF 억제제.
  9. 제5항에 있어서, TNF 억제제가 제38도에 도시된 아미노산 배열을 갖는 TNF 억제제.
  10. 제5항에 있어서, TNF 억제제가 40kDa TNF 억제제 ▲51 인 TNF 억제제.
  11. 제5항에 있어서, TNF 억제제가 40kDa TNF 억제제 ▲53 인 TNF 억제제.
  12. 하기 단계를 포함하는, TNF 억제제 생성을 위한 재조합 DNA 방법:
    (a) 숙주세포가 TNF 억제제 활성을 갖고 단백질을 생성하게 할 수 있는 DNA 배열의 제조; (b) 세포로 전이되어 전체 세포내에 복제될 수 있으며, DNA 배열을 발현하는데 필요한 작동요소를 함유하고 있는 벡터속으로, DNA 배열을 클론화; (c) 합성 DNA 배열 및 작동요소를 함유하고 있는 벡터를, TNF 억제제를 코드화하는 DNA를 발현할 수 있는 숙주로 전이; (d) 벡터의 증폭 및 억제제의 발현에 적절한 조건하에서 숙주세포를 배양; (e) 억제제를 수확; 및 (f) 억제제가 활성 3차 구조를 취하여 TNF 억제 활성을 소유하도록 허용.
  13. 제12항에 있어서, TNF 억제제가 30kDa TNF 억제제인 방법.
  14. 제12항에 있어서, TNF 억제제가 40kDa TNF 억제제인 방법.
  15. 제14항에 있어서, TNF 억제제가 40kDa TNF 억제제 ▲51인 방법.
  16. 제14항에 있어서, TNF 억제제가 40kDa TNF 억제제 ▲53인 방법.
  17. 종양괴사인자(TNF) 억제제에 대하여 코드화하는 유전자.
  18. 제17항에 있어서, TNF 억제제가 30kDa TNF 억제제인 유전자.
  19. 제17항에 있어서, TNF 억제제가 숙성 40kDa TNF 억제제인 유전자.
  20. 제17항에 있어서, TNF 억제제가 40kDa TNF 억제제 ▲51인 유전자.
  21. 제17항에 있어서, TNF 억제제가 40kDa TNF 억제제 ▲53인 유전자.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900010841A 1989-07-18 1990-07-18 종양괴사인자 억제제 및 그 제조방법 KR100230156B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US38108089A 1989-07-18 1989-07-18
US07381080 1989-07-18
US7/381,080 1989-07-18
US45032989A 1989-12-11 1989-12-11
US07450329 1989-12-11
US7/450,329 1989-12-11
US47966190A 1990-02-07 1990-02-07
US7/479,661 1990-02-07
US07479661 1990-02-07

Publications (2)

Publication Number Publication Date
KR910015309A true KR910015309A (ko) 1991-09-30
KR100230156B1 KR100230156B1 (ko) 1999-11-15

Family

ID=27409520

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900010841A KR100230156B1 (ko) 1989-07-18 1990-07-18 종양괴사인자 억제제 및 그 제조방법

Country Status (21)

Country Link
US (1) US6541620B1 (ko)
EP (2) EP0422339B1 (ko)
JP (1) JPH03163099A (ko)
KR (1) KR100230156B1 (ko)
AT (1) ATE162801T1 (ko)
AU (1) AU647397B2 (ko)
CA (1) CA2021369A1 (ko)
DE (1) DE69031997T2 (ko)
DK (1) DK0422339T3 (ko)
ES (1) ES2116970T3 (ko)
FI (1) FI114398B (ko)
GR (1) GR3026416T3 (ko)
HK (1) HK1014539A1 (ko)
IE (2) IE902608A1 (ko)
IL (2) IL95031A (ko)
NO (1) NO306728B1 (ko)
NZ (1) NZ234499A (ko)
PL (1) PL168844B1 (ko)
PT (1) PT94754B (ko)
SG (1) SG55131A1 (ko)
TW (1) TW206234B (ko)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811261A (en) * 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
EP0393438B1 (de) 1989-04-21 2005-02-16 Amgen Inc. TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6262239B1 (en) 1989-05-18 2001-07-17 Yeda Research And Development Co., Ltd. TNF receptor-specific antibodies
US6232446B1 (en) 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5304634A (en) * 1990-10-12 1994-04-19 Hoechst Aktiengesellschaft Inhibitors for the formation of tumor necrosis factor
GB9027917D0 (en) 1990-12-21 1991-02-13 Ici Plc Expression systems
JP2864434B2 (ja) * 1991-01-18 1999-03-03 サイナーゲン，インコーポレーテッド 腫瘍壊死因子媒介疾患の治療方法
EP0670730B1 (en) * 1992-03-30 2003-06-04 Immunex Corporation Fusion protein comprising two tumor necrosis factor receptors
PT639079E (pt) * 1992-04-30 2000-04-28 Amgen Inc Composicao para tratamento de doencas mediadas por interleuquina-1 e factor de necrose tumoral
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
IL125552A0 (en) 1996-02-09 1999-03-12 Amgen Inc Composition comprising interleukin-1 inhibitor and controlled release polymer
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
DE69738948D1 (de) 1996-12-06 2008-10-09 Amgen Inc Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
CA2273850A1 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
ES2231757T3 (es) * 1997-09-05 2005-05-16 Glaxo Group Limited Composiciones farmaceutica que comprenden derivados de 2,3-diaril-pirazolo (1,5-b) piridazina.
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU4541101A (en) 2000-03-02 2001-09-12 Xencor Inc Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
AR030554A1 (es) 2000-03-16 2003-08-27 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
US7879448B2 (en) * 2000-07-11 2011-02-01 Guardian Industires Corp. Coated article with low-E coating including IR reflecting layer(s) and corresponding method
DE60138715D1 (de) 2000-09-05 2009-06-25 Amgen Inc Tnf-rezeptor-ähnliche moleküle und deren anwendungen
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
JP2006517191A (ja) 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
EP1684791A4 (en) 2003-10-27 2009-07-01 Amgen Inc COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
US7785834B2 (en) * 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
WO2007058894A2 (en) * 2005-11-10 2007-05-24 The University Of North Carolina At Chapel Hill Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US20090264353A1 (en) * 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US8293100B2 (en) 2009-03-13 2012-10-23 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
SG182468A1 (en) 2010-01-15 2012-08-30 Kirin Amgen Inc Antibody formulation and therapeutic regimens
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
JP6596014B2 (ja) 2014-03-31 2019-10-23 アムジェン ケー・エー，インコーポレイテッド 爪および頭皮乾癬の治療方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IN150740B (ko) 1978-11-24 1982-12-04 Hoffmann La Roche
US4560649A (en) 1981-10-15 1985-12-24 Cornell Research Foundation Assaying for hLH or hCG with immobilized hormone receptors
JPH0751511B2 (ja) 1982-03-15 1995-06-05 味の素株式会社 インターロイキン２を含有してなる癌治療剤
US4587046A (en) 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4966888A (en) 1985-07-08 1990-10-30 Cornell Research Foundation, Inc. hCG-hLH receptor and hCG-hLH receptor-hCG complex as antigens, antibodies thereto and contraceptive vaccine
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
CA1339269C (en) 1984-05-21 1997-08-12 Douglas P. Cerretti Purification of and cloning of the gene for interleukin-2 receptor
US4578335A (en) 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
US4675285A (en) 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
CA1283046C (en) 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
IN165717B (ko) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4931544A (en) 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
IL80005A (en) 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US5512544A (en) 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5153265A (en) 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
GB8806339D0 (en) 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) * 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
US5214131A (en) 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5811261A (en) 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE3913101A1 (de) 1989-04-21 1990-10-31 Boehringer Ingelheim Int Tnf-(alpha) bindende proteine und dafuer kodierende dnas
JPH03164179A (ja) * 1989-04-21 1991-07-16 Boehringer Ingelheim Internatl Gmbh Ｔｎｆレセプター、ｔｎｆ結合たん白質およびこれらをコードするｄｎａ
DE3920282A1 (de) 1989-06-21 1991-01-03 Boehringer Ingelheim Int Tnf-rezeptor, tnf bindende proteine und dafuer kodierende dnas
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
EP0393438B1 (de) * 1989-04-21 2005-02-16 Amgen Inc. TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
ATE119942T1 (de) * 1989-05-18 1995-04-15 Yeda Res & Dev Tumor-nekrosefaktor-bindungsprotein ii, seine reinigung und spezifische antikörper.
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
WO1991003553A1 (en) 1989-09-05 1991-03-21 Immunex Corporation TUMOR NECROSIS FACTOR-α AND -β RECEPTORS
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
ATE128184T1 (de) 1989-12-13 1995-10-15 Yeda Res & Dev Expression des rekombinanten tumor-nekrosisfaktor-bindungsproteins i (tbp-i).
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
AU657483B2 (en) 1990-07-20 1995-03-16 Pharmacia Ab Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2864434B2 (ja) 1991-01-18 1999-03-03 サイナーゲン，インコーポレーテッド 腫瘍壊死因子媒介疾患の治療方法
JPH06508985A (ja) 1991-02-27 1994-10-13 クリエイティブ　バイオモレキュルズ　インコーポレイテッド 富セリンペプチドリンカー
EP0575545B1 (en) * 1991-03-15 2003-05-21 Amgen Inc. Pegylation of polypeptides
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
AU670125B2 (en) 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications

Also Published As

Publication number Publication date
NO306728B1 (no) 1999-12-13
US6541620B1 (en) 2003-04-01
DK0422339T3 (da) 1998-09-23
EP0422339A1 (en) 1991-04-17
HK1014539A1 (en) 1999-09-30
ES2116970T3 (es) 1998-08-01
SG55131A1 (en) 1998-12-21
IE990595A1 (en) 2000-11-15
PL168844B1 (pl) 1996-04-30
IL95031A0 (en) 1991-06-10
IL131281A0 (en) 2001-01-28
PL286089A1 (en) 1991-07-29
NO903192D0 (no) 1990-07-17
DE69031997D1 (de) 1998-03-05
IE902608A1 (en) 1991-02-27
NO903192L (no) 1991-01-21
GR3026416T3 (en) 1998-06-30
EP0790306A3 (en) 1998-07-01
NZ234499A (en) 1992-08-26
IL95031A (en) 2007-03-08
KR100230156B1 (ko) 1999-11-15
TW206234B (ko) 1993-05-21
PT94754A (pt) 1991-03-20
DE69031997T2 (de) 1998-05-14
AU647397B2 (en) 1994-03-24
FI903591A0 (fi) 1990-07-16
NO306728B3 (ko) 2003-02-17
EP0422339B1 (en) 1998-01-28
EP0790306A2 (en) 1997-08-20
PT94754B (pt) 1997-04-30
FI114398B (fi) 2004-10-15
JPH03163099A (ja) 1991-07-15
CA2021369A1 (en) 1991-01-19
ATE162801T1 (de) 1998-02-15
AU5897690A (en) 1991-01-24

Similar Documents

Publication Publication Date Title
KR910015309A (ko) 종양괴사인자(tnf) 억제제 및 그 제조방법
LU90408I2 (fr) Regranex-becaplermin
KR900700618A (ko) 인터루킨-1억제제
CA2033176A1 (en) Growth hormone fusion proteins
AU590896B2 (en) Improved formulations for recombinant beta-interferon
NO872932L (no) Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika.
NZ233642A (en) Linked hemoglobin subunits, preparation by genetic engineering and linker assay
ES2038579T1 (es) Una celula de levadura del genero schwanniovices.
DE59610632D1 (de) Varianten des humanen rekombinanten interferon-gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
KR840001836A (ko) 생리활성 물질의 제법
EP0111814A3 (en) The cloning and expression of nucleotide sequences encoding bovine growth hormone
ES2074046T5 (es) Procedimiento de construccion de una linea celular animal para la preparacion de beta-interferon humano.
DE69019230D1 (de) Herstellung von stabilisierten, lebensfähigen, sporenbildenden Mikroorganismen, ihre Produktion und deren Gravulatform.
EP0067697B1 (en) Cell culture method
KR840008697A (ko) 상동 효모 신호를 이용한 이종단백질의 합성, 분비 및 표현매개체 제조방법
WO2000029551B1 (en) Cells, culture methods, and their use in autologous transplantation therapy
ATE95564T1 (de) Aeusseres membranprotein f von pseudomonas aeruginosa.
ES2004099A6 (es) Procedimiento de preparacion de polipeptidos biologicamente activos
CA2172398A1 (en) Methods and products for controlling immune responses in mammals
DE69735694T2 (de) Polypeptide mit L-Asparaginase Aktivität
EP0106309A3 (de) Biologisch aktive Extrakte, Verfahren zu deren Herstellung, sie enthaltende pharmazeutische und kosmetische Mittel und ihre Verwendung als Zusätze für Lebens- und Genussmittel
Proost et al. Purification, sequence analysis, and biological characterization of a second bovine monocyte chemotactic protein-1 (Bo MCP-1B)
Metwali et al. Granuloma eosinophils enhance IL-5 production by lymphocytes from mice infected with Schistosoma mansoni.
Sinha Pepsin-like activity in the midgut of Sarcophage ruficornis and Musca domestica.
KR900006516A (ko) 소의 트로포블라스트 단백질-1의 유전자를 코딩하는 상보적 dna 및 그의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110728

Year of fee payment: 13

LAPS Lapse due to unpaid annual fee